Search
Tasimelteon
go.drugbank.com/drugs/DB09071ApprovedInvestigationalOccurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. … Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD).
NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 5, mitochondrial
go.drugbank.com/bio_entities/BE0000243TargetHumansAccessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. … Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone
Synonyms: Complex I-SGDHNADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6
go.drugbank.com/bio_entities/BE0000376TargetHumansAccessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. … Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone
Synonyms: Complex I-B17NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial
go.drugbank.com/bio_entities/BE0000676TargetHumansAccessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. … Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone
Synonyms: Complex I-ASHIOsimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigationaltesting and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. … Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexDelafloxacin
go.drugbank.com/drugs/DB11943ApprovedInvestigationalDelafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections,
Casirivimab
go.drugbank.com/drugs/DB15941ApprovedInvestigationalCasirivimab is a monoclonal antibody combined with [Imdevimab] in Regeneron's antibody cocktail known as REGN-COV2 for the treatment of COVID-19. … Casirivimab and imdevimab are investigational recombinant human IgG1 monoclonal antibodies that, at this time, are not officially approved by the FDA.
Nitrous oxide
go.drugbank.com/drugs/DB06690ApprovedInvestigationalVet approvedAt room temperature, it is a colorless non-flammable gas, with a pleasant, slightly sweet odor and taste. It is used in surgery and dentistry for its anesthetic and analgesic effects. … Nitrous oxide, commonly known as "laughing gas", is a chemical compound with the chemical formula N2O.
Mixtures: OXICALM® MEZCLA MEDICINAL DE OXIGENO: OXIDO NITROSOProducts: N/AJojoba oil
go.drugbank.com/drugs/DB14252ApprovedJojoba oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Mixtures: Anbiser B-HA Hyaluronic Acid Nourishing ConditionerEntrectinib
go.drugbank.com/drugs/DB11986ApprovedInvestigational[L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. … This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets.[A183929]
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index